The bill includes two provisions that would address drugmakers' calls for clarity on sharing off-label information with payers and regulators.
The CMS spent more on Harvoni than any other drug; Novartis considers selling Alcon; the EMA recommends approval of Lantus biosimilar
Trump says he will reform the FDA; pharmaceutical M&A expected to pick up; superbug causing infections in cystic-fibrosis patients
The FDA asked questions about the risks and benefits of allowing off-label communications.
FDA solicits public comment to study online character space limit; Biogen's Spinraza shows positive results in SMA study; Valeant cuts earnings forecast
Spurred by recent lawsuits, the FDA is scheduled to hold a two-day hearing this week on whether to allow drugmakers more latitude in promoting therapies off-label.
Here are 5 statistics about off-label promotion ahead of the FDA's public hearing this week.
Supernus Pharmaceuticals received an untitled letter over a promotional video for Oxtellar XR.
With lawmakers, patients, and physicians crying foul over pricing, drugmakers are trying to shift the narrative — with mixed results. Can a new focus on storytelling help?
The number of warning and untitled letters has dropped in recent years. Only four letters have been sent so far this year, compared to 28 in 2012.
Now here comes the big question. Will the shareholders and directors of KaloBios and Allergan reward or punish their CEOs for what some may see as revenue-capping concessions?
Lawmakers ask for information about price of leukemia drug; Abbott writes down losses from Mylan stake; CVS Health focused on role as health brand
More drugmakers file lawsuits to prevent biosimilar competition; experimental dermatitis drug showeds promising results; pharma blames PBMs for price hikes
For some people in the industry ecosystem, the appeal of promo knickknacks endures.
Five decades ago, pharmaceuticals were the protected province of health professionals. Today we have DTC ads, the internet, and pharmacy handouts.
The agency denied Pain Therapeutics' and Durect's abuse-deterrent opioid in a complete response letter after warning the drugmakers about how they promoted the drug.
Mylan CEO comes under fire at House Committee hearing; Abbott OxyContin reps went to great lengths to sell the pain pill; UnitedHealth drops Lantus
The OPDP sent its second untitled letter this week, this time to Durect and Pain Therapeutics over the presentation of Remoxy ER.
The regulator cited inconsistencies with how safety trial data was recorded in a report released ahead of the advisory committee's meeting on Wednesday.
A new study found that orphan drug spending will slow through 2018; senators open inquiry into Mylan; Shires launches branded campaign
The regulator charged Celator Pharmaceuticals with promoting an experimental drug as safe and effective even though it has not been approved.
BIO launches ad campaign defending drugmakers; GSK's experimental COPD drug reduces flare-ups in patients; NY attorney general to investigate Mylan
MannKind plans to develop inhalable epinephrine; lawmakers accuse Mylan of evading paying higher Medicaid rebates; NICE rejects Roche's cancer drug
The FDA will hold a public hearing in November to gather input on how it should regulate certain off-label communications.
Grassley blasts Mylan over EpiPen price increases; Portola Pharmaceuticals receives CRL letter for reversal agent; the FDA approves Pfizer's opioid
PhRMA and BIO, which represent life sciences firms, developed principles about sharing truthful and non-misleading information with payers and providers.
Lynn Fox is suing W2O. She was laid off in March, seven months after the agency network bought her San Francisco-based boutique, Fox Communications.
Darzalex may interfere with blood testing; Kaine scrutinized for ties to pharma; medical societies are in support of bill exempting CME reporting
Spending on CME rose in 2015; the FDA approves Valeant's Relistor; the Justice Department aims to block insurer merger
FDA Commissioner Robert Califf has two plans for what he wants to achieve during his tenure. One is long-term. The other ends in early 2017.
- Lilly's branded app for Trulicity looks to address adherence
- Lawmakers cut CME exemption from 21st Century Cures Act
- Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.
- Five things for pharma marketers to know: Tuesday, November 29, 2016
- Five things for pharma marketers to know: Wednesday, November 30, 2016
- Boehringer Ingelheim launches gamified support program
- Omnicom merges AgencyRx, Flashpoint and three other agencies to form DDB Health
- No free lunch for docs: Sponsored meals linked to more prescriptions
- Non-profit behind Free Killer Tan wants parents to practice sun safety
- Allergan draws on A-list celebs to drive engagement
- Rock Health's Bill Evans on finding a career with meaning
- Matt Brown leaves Guidemark Health after merger falls through
- Five things for pharma marketers to know: Monday, December 5, 2016
- Prescription drug spending rises 9% in 2015, to $324 billion
- As users move to mobile, Google says they made 200 million queries for info about cancer drugs